Wystepowanie beta-laktamaz typu ESBL u paleczek z rodzaju Serratia

• Autorzy: Ulatowska B. , Czajkowski H. , Gospodarek H. , Mikucka A.
• Języki publikacji: PL

Abstrakty

PL

Enzymy o rozszerzonym spektrum działania (ESBL) wśród klinicznych szczepów pałeczek z rodzaju Serratia wykrywano metodą dwóch krążków (w niewielkiej modyfikacji). Badania wykazały, że 57,7% szczepów dawało reakcję dodatnią.

EN

Serratia spp. has been identified as an important opportunistic pathogen agent in nosocomial infections. The aim of the study was the determination of extended spectrum ß-lactamases (ESBL) occurrence among 78 of Serratia spp. strains isolated in 1996-1998 from clinical specimens obtainted from patients of State Clinical Hospital in Bydgoszcz. Identification of Serratia spp. strains was performed in automatic ATB system with ID 32GN strips (bioMérieux). The strains with ESBL activity were detected by double-disc method according to Jarlier et al. (10) with small modifications. Clavulanic acid, tazobactam and sulbactam were used as the inhibitors of ESBLs. Drug-susceptibility was determinated by disc-diffusion method according to NCCLS standards. Forty-five (57,7%) of the strains were ESBL (+). All of them belonged to S. marcescens species. The majority - 91,1% of strains was derived from urine, 3 from wound and 1 from blood. The obtained results indicate the necessity of monitoring of ESBL-producing strains among gram-negative rods from clinical specimen. The aims of such a procedure are to control and to prevent their dissemination within hospital, as well as to avoid therapeutic failures.

Słowa kluczowe

PL

infekcja bakteryjna; wystepowanie; beta-laktamaza; szczepy kliniczne; enzymy; mikrobiologia; Serratia

• Wydawca: -
• Czasopismo: Medycyna Doświadczalna i Mikrobiologia
• Rocznik: 2000
• Tom: 52
• Numer: 1
• Opis fizyczny: s.17-24,rys.,bibliogr.

Twórcy

autor

Ulatowska B.

• Akademia Medyczna, 85-094 Bydgoszcz, ul.M.Sklodowskiej-Curie 9

autor

Czajkowski H.

autor

Gospodarek H.

autor

Mikucka A.

Bibliografia

• 1. Andrzejewska E, Szkaradkiewicz A, Kaniasty M. Wrażliwość na wybrane antybiotyki ß-laktamowe klinicznych szczepów Escherichia coli i Klebsiella pneumoniae. Med Dośw Mikrobiol 1998; 50: 197-205.
• 2. Bollmann R, Halle E, Sokolowska-Köhler W i inni. Nosocomial infections due to Serratia marcescens-clinical findings, antibiotic susceptibility patterns and fine typing. Infection 1989; 17: 294-300.
• 3. Chanal CM, Sirot DL, Petit A i inni. Multiplicity of TEM-derived ß-lactamases from Klebsiella pneumoniae strains isolated at the same hospital and relationships between the responsible plasmids, Antimicrob Agents Chemother 1989; 33: 1915-20.
• 4. Chaudhuri AK, Both CF. Outbreak of chest infections with Serratia marcescens. J Hosp Infect 1992; 22: 169-70.
• 5. Coudron PE, Moland ES, Sanders C. Occurrence and detection of extended-spectrum ß-lactamases in members of the family Enterobacteriaceae at a veterans medical center: seek and may find. J Clin Microbiol 1997; 10: 2593-97.
• 6. Gniadkowski M, Trzciński K, Pałucha A i inni. Wykrywanie ß-laktamaz o rozszerzonym zakresie działania (ESL) w izolatach klinicznych Klebsiella pneumoniae : test dwóch krążków i test ATB BLSE Diag Lab 1996; 32: 697-709.
• 7. Gałuszko P. Ekspresja czynników wirulencji oraz lekoopomości u wariantów morfologicznych dysocjujących szczepów Serratia marcescens. Praca habilitacyjna, Bydgoszcz 1996.
• 8. Gospodarek E, Czajkowski H, Ulatowska B, Bacteria of Serratia genus as aetiological factor of hospital infections. Med Sci 1998; 6; 1024-29.
• 9. Hryniewicz W, Trzciński K. Zasady doboru testów wrażliwości bakterii na chemioterpeutyki. Mikrobiol Med 1998; 1: 22-32.
• 10. Jarlier V, Nicolas M, Fournier G i inni. Extended broad-speetrum ß-lactamases conferring transferable resistance to newer ß-lactam agents in Enterobacteriaceae hospital prevalence and susceptibility patterns. Rev Infect Dis 1988; 10: 867.
• 11. Jorvis WR, Edwards JR. Culver DH i inni. Nosocomial infection rates in adult and pediatric intensive care units in the United States. Am J Med 1991; S3B; 185S-191A.
• 12. Knothe A, Shah P, Kremy V i inni. Transferable - resistance of cefotaxime, cefoxitin, cefamandole and cefuruxime in clinical isolates of Klebsiella pneumoniae and Serratia marcescens. Infection 1983; 11: 315-17.
• 13. Koppstein I, Duschner FD. Nosocomial infections in intensive care units. Curr Opin Infect Dis 1990; 3: 509-16.
• 14. Livermore D. ß-Iactamases in laboratory and clinical resistance. Clin Microb Rev 1995; 8: 557.
• 15. Mariotte S, Normann P, Nicolas MH. Extended spectrum -lactamase in Proteus mirabilis. J Antimicrob Chemother 1994; 33: 925-35.
• 16. Philippon A, Ben Redjeb S, Fournier G i inni. Epidemiology of extended spectrum ß-lactamases. Infection 1989; 17: 347-54.
• 17. Preference Standards for Antimicrobiol Disc Susceptibility tests. Sixth edition. Aproved Standards. NCCLS Document M2-A6, 1997.
• 18. Sanders CC, Sanders WE Jr. Clinical importance of inducible beta-lactamase in gram-negative bacteria. Eur J Clin Microbiol 1987; 6: 435-37.
• 19. Sanders CC. Chromosomal cephalosporinases responsible for multiple resistance to newer ß-lactam antibiotics. Ann Rev Microbiol 1987; 41: 573-93.
• 20. Thomas KS, Sanders CC. Detection of extended spectrum ß-lactamases in members of the family Enterobacteriaceae: comparison of the double-disc and three-dimensional tests. Antimicrob Agents Chemother 1992; 8: 1877-82.